Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Does Disease-Irrelevant Intrathecal Synthesis in Multiple Sclerosis Make Sense in the Light of Tertiary Lymphoid Organs?
Selective inhibition by riluzole of voltage-dependent sodium channels and catecholamine secretion in adrenal chromaffin cells.
Vowel Acoustics in Parkinson's disease and Multiple Sclerosis: Comparison of Clear, Loud and Slow Speaking Conditions.
Analyzing differences between patient and proxy on Patient Reported Outcomes in multiple sclerosis.
Demyelination and other neurological adverse events after anti-TNF therapy.
The Impact of Interferon Beta and Natalizumab on Comorbid Migraine in Multiple Sclerosis.
Subject movement during multislice interleaved MR acquisitions: Prevalence and potential effect on MRI-derived brain pathology measurements and multicenter clinical trials of therapeutics for multiple sclerosis.
Immunomodulatory synergy by combining atorvastatin and rapamycin in the treatment of experimental autoimmune encephalomyelitis (EAE).
Opioid growth factor arrests the progression of clinical disease and spinal cord pathology in established experimental autoimmune encephalomyelitis.
Walking speed, rather than Expanded Disability Status Scale, relates to long-term patient-reported impact in progressive MS.
Personalized medicine in multiple sclerosis: hope or reality?
[The quality of nighttime sleep in patients with multiple sclerosis].
Application of laser radiation and magnetostimulation in therapy of patients with multiple sclerosis.
Neuromyelitis optica in pregnancy complicated by posterior reversible encephalopathy syndrome, eclampsia and fetal death.
Disease mechanisms in MS: RNA profiling uncovers two distinct subsets of patients with multiple sclerosis.
Resistance training and vibration improve muscle strength and functional capacity in female patients with multiple sclerosis.
Toxoplasmosis and Polygenic Disease Susceptibility Genes: Extensive Toxoplasma gondii Host/Pathogen Interactome Enrichment in Nine Psychiatric or Neurological Disorders.
Supporting work for people with multiple sclerosis.
The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis.
Multiple Sclerosis and CCSVI: A Population-Based Case Control Study.
[Amino acids content in the blood serum of patients with multiple sclerosis.]
Central nervous system demyelinating disease-associated uveitis.
Chromosomal radiosensitivity in patients with multiple sclerosis.
Prolactin Is Not Required for the Development of Severe Chronic Experimental Autoimmune Encephalomyelitis.
In vivo imaging of activated microglia in a mouse model of focal cerebral ischemia by two-photon microscopy.
Pages
« first
‹ previous
…
315
316
317
318
319
320
321
322
323
…
next ›
last »